Pulse Biosciences Reports Sustained Thyroid Nodule Reduction with nsPFA Technology
Event summary
- 15-22 month follow-up shows 74% average volume reduction in benign thyroid nodules using nsPFA technology.
- No regrowth or serious adverse events reported, with 100% cosmetic satisfaction and 95% overall patient satisfaction.
- Data presented at North American Society for Interventional Thyroidology meeting on March 6, 2026.
- Study involved 21 patients treated at Ospedale del Mare in Naples, Italy.
The big picture
The sustained efficacy of Pulse Biosciences' nsPFA technology in benign thyroid nodule ablation positions it as a potential disruptor in the $2B+ global thyroid treatment market. The nonthermal approach offers procedural safety advantages, but scaling beyond niche applications will require further clinical validation and regulatory milestones.
What we're watching
- Market Expansion
- Whether Pulse Biosciences can leverage these results to accelerate non-cardiac nsPFA applications.
- Regulatory Pathway
- The pace at which long-term durability data will support broader commercialization efforts.
- Competitive Positioning
- How nsPFA's nonthermal differentiation will impact adoption against existing ablation technologies.
Our editorial coverage:
Related topics